Zenas BioPharma Inc.
Organization details
- Legal name
- Zenas BioPharma Inc.
- Former names
- Zenas BioPharma (Cayman) Ltd
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Waltham
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ZBIO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001953926
Board of directors
- Since 2026
-
Hongbo Lu · DirectorSince 2024
-
James P. Boylan · DirectorSince 2024
-
Jason Raleigh Nunn · DirectorSince 2024
-
John J. Orloff · DirectorSince 2024
-
Leon O. Moulder Jr. · Director · See RemarksSince 2024
-
Patricia L. Allen · DirectorSince 2024
- Since 2024
- Since 2024
-
Ting Xiao · DirectorSince 2024
- Since 2024
Chief executives
Weak · grade F
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 0
-55.3% a year in revenue
20% of the scoring weight is on file. Figures cover December 2023 – December 2025.
Director election results
Annual meeting of May 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
91.5%
-
91.8%
Board connections
8 of this board's directors also sit on 22 other boards. 22 are in the same sector.
-
Dianthus Therapeutics Inc. Same sectorvia Leon O. Moulder Jr., Peter Evan Harwin and Tomas Kiselak
-
Crescent Biopharma Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Jade Biosciences Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Korsana Biosciences Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Oruka Therapeutics Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Spyre Therapeutics Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Vera Therapeutics Inc. Same sectorvia Christy J. Oliger and Patrick G. Enright
-
Viridian Therapeutics Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Addex Therapeutics Ltd Same sectorvia Jason Raleigh Nunn
-
Arrowhead Pharmaceuticals Inc. Same sectorvia Hongbo Lu
-
Bicara Therapeutics Inc. Same sectorvia Christy J. Oliger
-
BioAge Labs Inc. Same sectorvia Patrick G. Enright
-
CAMP4 Therapeutics Corporation Same sectorvia James P. Boylan
-
Cogent Biosciences Inc. Same sectorvia Peter Evan Harwin
-
Compass Therapeutics Inc. Same sectorvia James P. Boylan
-
Damora Therapeutics Inc. Same sectorvia Peter Evan Harwin
-
Immunome Inc. Same sectorvia James P. Boylan
-
Jazz Pharmaceuticals plc Same sectorvia Patrick G. Enright
-
Karyopharm Therapeutics Inc. Same sectorvia Christy J. Oliger
-
Replimune Group Inc. Same sectorvia Christy J. Oliger
-
Veradermics Incorporated Same sectorvia Patrick G. Enright
-
Zai Lab Limited Same sectorvia Leon O. Moulder Jr.
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $11,418,466
- 17 purchases by 4 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 18, 2026 | Leon O. Moulder Jr. Director, Officer (Chief Executive Officer) | Open-market purchase | +60,000 | $16.88 | $1,012,800 |
| Apr 29, 2026 | Leon O. Moulder Jr. Director, Officer (Chief Executive Officer) | Open-market purchase | +35,000 | $17.62 | $616,700 |
| Apr 28, 2026 | Leon O. Moulder Jr. Director, Officer (Chief Executive Officer) | Open-market purchase | +25,000 | $18.02 | $450,500 |
| Mar 31, 2026 | Hongbo Lu Director | Open-market purchase | +75,000 | $20.00 | $1,500,000 |
| Mar 31, 2026 | Hongbo Lu Director | Open-market purchase | +3,768 | $18.63 | $70,198 |
| Mar 31, 2026 | Tomas Kiselak Director | Open-market purchase | +150,000 | $20.00 | $3,000,000 |
| Mar 31, 2026 | Leon O. Moulder Jr. Director, Officer (Chief Executive Officer) | Open-market purchase | +34,000 | $19.31 | $656,540 |
| Mar 30, 2026 | Leon O. Moulder Jr. Director, Officer (Chief Executive Officer) | Open-market purchase | +20,000 | $18.23 | $364,600 |
| Feb 13, 2026 | Patricia L. Allen Director | Open-market purchase | +4,160 | $26.36 | $109,658 |
| Feb 12, 2026 | Patricia L. Allen Director | Open-market purchase | +5,000 | $23.77 | $118,850 |
| Feb 12, 2026 | Patricia L. Allen Director | Open-market purchase | +5,700 | $24.34 | $138,738 |
| Feb 12, 2026 | Patricia L. Allen Director | Open-market purchase | +5,000 | $26.50 | $132,500 |
| Feb 11, 2026 | Hongbo Lu Director | Open-market purchase | +25,985 | $22.50 | $584,663 |
| Feb 5, 2026 | Farmer Joseph L Officer (See Remarks) | Grant or award | +974 | $13.35 | $13,003 |
| Feb 5, 2026 | Jennifer A. Fox Officer (See Remarks) | Grant or award | +1,592 | $13.35 | $21,253 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Zenas BioPharma Inc.
Who is the CEO of Zenas BioPharma Inc.?
Leon O. Moulder Jr. has been Zenas BioPharma Inc.'s Chief Executive Officer since September 2024.
How many directors are on Zenas BioPharma Inc.'s board?
Zenas BioPharma Inc.'s board has 11 directors: Christy J. Oliger, Hongbo Lu, James P. Boylan, Jason Raleigh Nunn, John J. Orloff, Leon O. Moulder Jr., Patricia L. Allen, Patrick G. Enright, Peter Evan Harwin, Ting Xiao and 1 other.
Are Zenas BioPharma Inc. insiders buying or selling shares?
Over the last 12 months, Zenas BioPharma Inc. insiders bought $11.4 million of shares in 17 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="zenas-biopharma-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.